Osteopore (ASX:OSX) Total Stockholders Equity: A$-1.73 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Osteopore Total Stockholders Equity?

Osteopore ASX:OSX +12.50% Total Stockholders Equity is A$-1.73 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Osteopore's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$-1.73 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Osteopore's Book Value per Share for the quarter that ended in Dec. 2025 was A$-0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Osteopore's Debt-to-Equity for the quarter that ended in Dec. 2025 was -1.62.

Osteopore  (ASX:OSX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Osteopore's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-1.726-0)/272.502
=-0.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Osteopore's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.343 + 1.452) / -1.726
=-1.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Osteopore Total Stockholders Equity Related Terms

Osteopore Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Osteopore's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Osteopore Total Stockholders Equity Chart

Osteopore Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 5.37 2.11 0.43 0.31 -1.73

Osteopore Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 1.80 0.31 -0.42 -1.73
What does a Total Stockholders Equity of A$-1.73 Mil mean?
Osteopore (ASX:OSX) has a Total Stockholders Equity of A$-1.73 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Osteopore and its competitors.
Is Osteopore's Total Stockholders Equity too high?
Osteopore's current Total Stockholders Equity is A$-1.73 Mil.
How does Osteopore's Total Stockholders Equity compare to ISRG and BDX?
Osteopore's Total Stockholders Equity of A$-1.73 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Osteopore and its competitors. Osteopore's current Total Stockholders Equity is A$-1.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 77.5% below its estimated fair value. The current Total Stockholders Equity is A$-1.73 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current Total Stockholders Equity is A$-1.73 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Osteopore Business Description

Address 2 Tukang Innovation Grove, No. 09-06 and 07, JTC MedTech Hub, Singapore, SGP, 618305
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.